CHEST
Radiation is used to treat lung, breast, and esophageal cancers. Chest wall radionecrosis occurs most frequently after mastectomy because of the need to treat skin and subcutaneous tissues—after breast cancer, tumors often recur in the skin of the chest wall. Hart reported that skin grafts succeeded for all six patients with radiation injury who were treated with HBOT after grafting. Feldmeier reported that six of eight with soft tissue necrosis and eight of fifteen with soft tissue and bone necrosis responded with full resolution. Those with bone necrosis required resection of non-viable bone.
In 2001, Carl and Hartmann studied 44 patients with complications of early breast cancer lumpectomy and irradiation with fifteen 90-minute HBOT treatments at 2.4 ATA. Before treatment symptoms included pain, swelling (edema), thickening of tissue (fibrosis), and engorged capillaries (telengactasias). Of these patients, thirty-two agreed to undergo hyperbaric treatment; twelve refused. For those who were treated with HBOT, pain was markedly reduced, while seven had complete remission of symptoms by the end of the study. The control group experienced no improvement in pain or edema.
Radiation treatment of chest and chest wall (most commonly lung and breast malignancies) often results in lung inflammation, pneumonia, and collapsed lung. Initial treatment reduces the level of surfactant, which keeps air passages open. Breathing can be difficult, with the individual suffering cough and shortness of breath.
Radiation can also cause fibrosis, a stiffening or scarring of the lung which can restrict the full expansion required for breathing.
Less common is actual tissue death, but lung cancer, and mesothelioma, a cancer of the tissue surrounding the lungs and most often seen in persons exposed to asbestos, may occur. Nerve damage to the larynx (voice box) or the diaphragm can also result from radiation treatment.
Radiation-induced heart disease and arteriosclerosis are increasing in prevalence, as well as valve insufficiency, and muscle damage. Previous chemotherapy, total body irradiation, or concentrated administration adjacent to the heart or on the left side of the chest increase risks to the heart.